Sertraline vs. Paroxetine: FDA-Approved PTSD Medications

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 3, 2026 | 8 min read

Sertraline (Zoloft) and paroxetine (Paxil) are the only two FDA-approved medications for PTSD. This FDA approval directly ties the prescription to the accident-caused condition. Sertraline is generally preferred first-line, while paroxetine's use often signals treatment-resistant anxiety or prior SSRI failure.

Sertraline (Zoloft) and paroxetine (Paxil) are the only two medications with FDA approval specifically for the treatment of post-traumatic stress disorder. This distinction is the single most important pharmacological fact for personal injury attorneys handling PTSD cases: when a treating physician prescribes sertraline or paroxetine for PTSD, the prescriber is using the medication for its FDA-approved indication — the strongest possible prescribing defense against any challenge to medical necessity or causation. Both are selective serotonin reuptake inhibitors (SSRIs) that increase serotonin availability in the synaptic cleft, but they differ significantly in side effect profiles, drug interaction potential, and discontinuation risk.

• Sertraline and paroxetine are the ONLY two FDA-approved medications for PTSD — no other antidepressant, anxiolytic, or psychiatric medication holds this approval
• Sertraline is generally preferred first-line due to fewer drug interactions, a more favorable weight profile, and easier discontinuation
• Paroxetine is the most potent SSRI for anxiety but carries the worst discontinuation syndrome of any SSRI, significant weight gain, and strong anticholinergic effects
• When paroxetine is prescribed over sertraline, it often signals that sertraline was tried and failed or that the anxiety component is so severe that the most potent anxiolytic SSRI was clinically necessary
• FDA approval for PTSD means the prescribing decision is on-label — the strongest defense against claims that the medication is unrelated to the injury

[!KEY] The FDA approval distinction cannot be overstated for PI case documentation. When any other psychiatric medication is prescribed for PTSD (venlafaxine, prazosin, mirtazapine), it is being used off-label. When sertraline or paroxetine is prescribed for PTSD, the prescriber is using the medication exactly as the FDA approved it. This makes causation arguments cleaner and defense challenges harder to sustain.

The FDA Approval Significance

The FDA approved sertraline for PTSD in 1999 (NDA 019839/S-023) and paroxetine for PTSD in 2001 (NDA 020031/S-032), based on large randomized controlled trials demonstrating statistically significant improvement in PTSD symptom severity compared to placebo. These remain the only two FDA-approved pharmacological treatments for PTSD to date.

What FDA approval means for a PI case:

• On-label prescribing: The physician is using the medication within its approved indication, not off-label. This eliminates the defense argument that the medication was prescribed experimentally or for a condition it was not designed to treat.
• Evidence-based standard of care: FDA approval required demonstration of efficacy in controlled clinical trials. The prescribing decision reflects established medical evidence, not clinical opinion alone.
• Insurance and formulary support: FDA-approved indications receive formulary coverage; off-label uses may not. This becomes relevant if pharmacy records are challenged during litigation.
• Expert testimony support: A treating physician testifying about prescribing an FDA-approved medication for its approved indication is on the strongest possible clinical ground.

Sertraline (Zoloft): The Preferred First-Line SSRI

Pharmacological Profile

Sertraline is a potent and selective inhibitor of the serotonin reuptake transporter (SERT) with minimal activity at other receptor systems. This selectivity contributes to its relatively clean side effect profile compared to other SSRIs. Sertraline has a half-life of approximately 26 hours, supporting once-daily dosing.

Key pharmacological advantages of sertraline:

• Low CYP2D6 inhibition: Sertraline is a mild inhibitor of the CYP2D6 hepatic enzyme, resulting in fewer clinically significant drug-drug interactions compared to paroxetine (which is a potent CYP2D6 inhibitor). For PI patients taking multiple medications — opioid analgesics, muscle relaxants, gabapentinoids — this is a meaningful safety advantage.
• More favorable weight profile: While all SSRIs can cause weight gain, sertraline is associated with less weight gain than paroxetine. Weight gain is a common reason patients discontinue antidepressants, and in PI cases, discontinuation destabilizes treatment.
• Easier discontinuation: Sertraline's discontinuation syndrome is mild to moderate compared to paroxetine's severe withdrawal profile. This matters at case resolution when the patient may taper off the medication.

Dosing for PTSD

• Starting dose: 25 mg once daily (often increased to 50 mg after one week)
• Therapeutic dose range: 50-200 mg once daily
• Typical effective PTSD dose: 100-150 mg daily
• Maximum dose: 200 mg daily

Side Effects

• Nausea (most common early side effect; typically resolves within 1-2 weeks)
• Diarrhea (more common with sertraline than other SSRIs due to high serotonergic activity in the GI tract)
• Insomnia or sleep disturbance
• Sexual dysfunction (dose-dependent)
• Headache
• Mild weight gain (less than paroxetine)
• Activation/restlessness in the initial 1-2 weeks

Why Sertraline Is Generally Prescribed First

Most PTSD treatment algorithms and clinical practice guidelines — including those from the VA/DoD, the American Psychiatric Association, and the International Society for Traumatic Stress Studies — recommend sertraline as the initial pharmacological treatment for PTSD. The rationale combines efficacy evidence, tolerability, safety in polypharmacy contexts, and the practical advantage of easier discontinuation when treatment ends.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist with clinical experience in psychiatric pharmacy, explains, "Sertraline's position as the default first-line SSRI for PTSD means that when we see paroxetine prescribed instead, it tells a clinical story. Either the prescriber already tried sertraline and the patient did not respond adequately, or the patient's anxiety and hyperarousal symptoms are severe enough that the prescriber went directly to the most potent anxiolytic SSRI available. Either way, the paroxetine prescription documents treatment complexity."

Paroxetine (Paxil): The Most Potent Anxiolytic SSRI

Pharmacological Profile

Paroxetine is the most potent serotonin reuptake inhibitor among the SSRIs, with the highest binding affinity for the serotonin transporter. Beyond SERT inhibition, paroxetine has clinically meaningful activity at several additional receptor systems:

• Muscarinic acetylcholine receptor antagonism: This anticholinergic activity contributes to side effects (dry mouth, constipation, urinary retention, cognitive blunting) but may also contribute to its sedating and anxiolytic properties.
• Norepinephrine reuptake inhibition (weak): At higher doses, paroxetine has mild NRI activity that may add to its anxiolytic effect.
• Potent CYP2D6 inhibition: Paroxetine is the strongest CYP2D6 inhibitor among the SSRIs, creating significant drug interaction potential with opioids (codeine, tramadol, hydrocodone conversion), beta-blockers, and other CYP2D6 substrates common in PI patients' medication regimens.

Why Paroxetine Is the Strongest Anxiolytic SSRI

Paroxetine's combination of high SERT potency, anticholinergic sedation, and mild NRI activity produces the most pronounced anxiolytic effect of any SSRI. For patients with severe PTSD hyperarousal, intense anxiety, and agitation, paroxetine may provide more symptom relief than sertraline — though at the cost of a heavier side effect burden.

This is why paroxetine is often reserved for cases where sertraline was inadequate or where the PTSD symptom profile is dominated by severe anxiety and hyperarousal that demands the most aggressive SSRI intervention.

Dosing for PTSD

• Starting dose: 20 mg once daily
• Therapeutic dose range: 20-50 mg daily
• Typical effective PTSD dose: 20-40 mg daily
• Maximum dose: 60 mg daily

The Discontinuation Syndrome Problem

Paroxetine has the worst discontinuation syndrome of any SSRI — a critical clinical fact for PI patients and their attorneys. Paroxetine withdrawal symptoms include:

• "Brain zaps": Electric shock-like sensations in the head, described by patients as sudden jolts or buzzing. These are the hallmark of paroxetine withdrawal and are distressing and disabling.
• Flu-like symptoms: Nausea, vomiting, diarrhea, chills, sweating, myalgia.
• Rebound anxiety and irritability: Often more intense than the original anxiety symptoms.
• Dizziness and vertigo: Can impair driving and daily function.
• Insomnia and vivid dreams: Sleep disturbance during discontinuation.
• Emotional lability: Crying spells, irritability, mood swings.

These symptoms can begin within 24-48 hours of a missed dose due to paroxetine's relatively short half-life (approximately 21 hours, shorter in some patients). Even gradual dose tapering over weeks may produce withdrawal symptoms.

[!KEY] Paroxetine's severe discontinuation syndrome is directly relevant to PI case management. Any gap in medication access — caused by financial barriers, pharmacy changes, insurance lapses, or prescription delays — can trigger debilitating withdrawal within 24-48 hours. LienScripts pharmacy liens prevent this by providing continuous access at $0 upfront cost. The MERIT (Medication Evaluation & Rationale for Injury Treatment) report documents the uninterrupted dispensing timeline, showing that treatment continuity was maintained throughout the case.

Weight Gain

Paroxetine causes more weight gain than any other SSRI. Studies report average weight increases of 5-10 pounds, with some patients gaining significantly more. The mechanism involves serotonergic effects on appetite regulation, anticholinergic-mediated metabolic changes, and reduced physical activity from sedation. This side effect is a common reason for patient dissatisfaction and can become a secondary issue in PI cases if weight gain exacerbates physical injury symptoms or contributes to depression.

Anticholinergic Effects

Paroxetine's muscarinic receptor antagonism produces anticholinergic side effects that are uncommon with sertraline:

• Dry mouth
• Constipation
• Urinary retention
• Blurred vision
• Cognitive blunting (particularly concerning in patients with concurrent TBI)

Head-to-Head Comparison

What the Prescribing Choice Signals in a PI Case

When Sertraline Is Chosen First

The prescribing physician is following standard first-line guidelines for PTSD treatment. This is the expected, evidence-based prescribing decision. The pharmacy record documents:

• A physician diagnosed PTSD and selected the guideline-recommended first-line FDA-approved medication
• The prescriber considered the patient's overall medication regimen and chose the SSRI with the fewest drug interactions
• The treatment approach is conservative, appropriate, and defensible

When Paroxetine Is Chosen

Paroxetine selection over sertraline signals one or more of these clinical scenarios:

1. Sertraline was tried and failed: The patient did not achieve adequate PTSD symptom control on sertraline, and the prescriber escalated to the more potent SSRI. The pharmacy record showing a sertraline trial followed by a switch to paroxetine documents treatment resistance — evidence of PTSD severity.
2. Severe anxiety/hyperarousal component: The prescriber assessed the patient's PTSD symptom profile as dominated by severe anxiety, panic, or hyperarousal that warranted the most potent anxiolytic SSRI from the start. This documents symptom severity.
3. Prior paroxetine response: The patient has a documented history of responding to paroxetine for anxiety or PTSD and the prescriber re-initiated a known effective medication.

In any of these scenarios, the paroxetine prescription strengthens the severity narrative in the demand package.

When a Patient Switches from Sertraline to Paroxetine

This switch is a documented treatment escalation. The pharmacy record shows: (1) initial treatment with the standard first-line SSRI, (2) inadequate response, (3) escalation to a more potent but higher-risk SSRI. This progression documents treatment complexity and PTSD severity — the patient's condition was severe enough to require stepping up to a medication with a more difficult side effect profile.

Drug Interaction Considerations for PI Patients

PI patients commonly take multiple concurrent medications — opioid analgesics, muscle relaxants, gabapentinoids, NSAIDs, sleep medications. Paroxetine's potent CYP2D6 inhibition creates clinically significant drug interactions that do not occur with sertraline:

• Codeine/tramadol: These opioids require CYP2D6 conversion to active metabolites. Paroxetine can block this conversion, reducing analgesic efficacy. A PI patient on paroxetine who "doesn't respond" to codeine or tramadol may be experiencing a drug interaction, not treatment failure.
• Hydrocodone: Partially converted by CYP2D6 to hydromorphone (a more potent metabolite). Paroxetine can reduce this conversion.
• Metoprolol: CYP2D6 substrate; co-administration with paroxetine can increase metoprolol levels and risk of bradycardia.

Sertraline's mild CYP2D6 inhibition makes these interactions far less likely, which is one reason it is preferred in the polypharmacy context of PI care.

[!KEY] When a PI patient is prescribed paroxetine despite the known drug interaction risks with their concurrent pain medications, this documents that the treating physician determined the PTSD was severe enough to accept these risks. The clinical risk-benefit analysis itself supports the severity claim.

Pharmacy Lien Coverage and MERIT Documentation

Both sertraline and paroxetine are covered under LienScripts pharmacy liens when prescribed for injury-related PTSD. Both are generic medications available at formulary pricing. LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages that identifies each medication, its FDA-approved PTSD indication, and the treatment timeline.

The MERIT report is particularly valuable for PTSD cases because it provides pharmacist-level clinical context explaining: (1) that the prescribed SSRI has FDA approval specifically for PTSD, (2) whether the prescription represents first-line treatment or an escalation from a prior SSRI trial, and (3) how the dispensing timeline correlates with the accident date and treatment progression.

Related Resources

• Prazosin vs. Propranolol for PTSD Nightmares After Accidents -- Alpha-1 blocker vs beta-blocker for trauma nightmares
• Hydroxyzine vs. Benzodiazepines for Post-Injury Anxiety -- Clinical comparison of anxiolytic approaches in PI cases
• What Is a MERIT Report? -- How pharmacy documentation supports demand packages